[go: up one dir, main page]

WO2007129184A2 - An improved process for the preparation of phenytoin sodium - Google Patents

An improved process for the preparation of phenytoin sodium Download PDF

Info

Publication number
WO2007129184A2
WO2007129184A2 PCT/IB2007/001130 IB2007001130W WO2007129184A2 WO 2007129184 A2 WO2007129184 A2 WO 2007129184A2 IB 2007001130 W IB2007001130 W IB 2007001130W WO 2007129184 A2 WO2007129184 A2 WO 2007129184A2
Authority
WO
WIPO (PCT)
Prior art keywords
phenytoin
sodium
water
preparation
dissolved
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2007/001130
Other languages
French (fr)
Other versions
WO2007129184A3 (en
Inventor
Siripragada Mahender Rao
Padmanabhan Ramar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Orchid Pharma Ltd
Original Assignee
Orchid Chemicals and Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orchid Chemicals and Pharmaceuticals Ltd filed Critical Orchid Chemicals and Pharmaceuticals Ltd
Publication of WO2007129184A2 publication Critical patent/WO2007129184A2/en
Anticipated expiration legal-status Critical
Publication of WO2007129184A3 publication Critical patent/WO2007129184A3/en
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72Two oxygen atoms, e.g. hydantoin
    • C07D233/74Two oxygen atoms, e.g. hydantoin with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to other ring members

Definitions

  • the present invention relates to an improved process for the preparation of Phenytoin Sodium, a sodium channel blocker used for the treatment of epilepsy.
  • Phenytoin Sodium which is chemically known as 5,5-Diphenylhydantoin sodium salt is a sodium channel blocker, and has the following structural formula:
  • Phenytoin Sodium is a well-known pharmaceutical agent having anticonvulsant and antiepileptic activity and useful in the treatment of epilepsy and it is available in the market under the various brand names such as Aleviatin ® , Persantin ® , Aurantin ® , Dilantin ® , Dintoina ® , Epanutin ® etc.
  • US Pat. No. 3,646,056 describes a process for the preparation of 5,5-diarylhydantoins in one step by reacting benzoin with 1-3 equivalents of urea in an alkaline medium in the presence of 0.5-4 equivalents of elemental sulfur at a temperature between 60° C and the boiling point of the reaction mixture.
  • US Pat. No. 6,245,917 teaches a process for the preparation of crystalline sodium phenytoin monohydrate by mixing sodium Phenytoin anhydrate and water in an organic solvent selected from toluene, methanol and dichloromethane, at about 30 0 C to about 40 0 C.
  • the main objective of the present invention is to provide an improved process for the preparation of compound of formula (I) in high yield and high purity.
  • Another objective of the present invention is to provide a process for the preparation of compound of formula (I), which uses water as a solvent and avoids organic solvents.
  • Another objective of the present invention is to provide a process for the preparation of compound of formula (I), which is economical and commercially viable.
  • the present invention provides a process for the preparation of Phenytoin Sodium (I), by reacting of Phenytoin of formula (II) with aqueous solution of sodium hydroxide in presence of aqueous Sodium chloride using water as a solvent at a temperature of about 25° C to 50° C to obtain Phenytoin Sodium of formula (I).
  • the aqueous sodium chloride is used in different concentration with respect to Phenytoin where the concentration varies from 10 to 50% preferably 20 to 40%.
  • the reaction is performed at a temperature of about 5° C to 50° C. Most preferably; the reaction step is performed at a temperature of about 5° C to 30° C.
  • the starting material of this invention is prepared according to the literature available in the prior art.
  • Phenytoin (2Og) was dissolved in 120 mL of DM water and Sodium hydroxide solution (3.56g dissolved in water 22.5mL) at 25-30 0 C in a 250 mL four-necked RBF. The reaction mixture was filtered and the clear filtrate was collected. The reaction mass was cooled to 5-10 0 C under nitrogen atmosphere and stirred for 60min. The solid was filtered under vacuum & nitrogen atmosphere and washed the product with 2OmL of chilled water. The solid was dried at 50-60 0 C under nitrogen atmosphere to obtain 14.4g of dry Phenytoin sodium. Yield: approx. 66.2% w.r.t. Phenytoin
  • Phenytoin (2Og) was dissolved in 120 mL of DM water and Sodium hydroxide solution (3.56g dissolved in water 22.5mL) at 25-30 0 C in a 250 mL four-necked RBF. The reaction mixture was filtered and the clear filtrate was collected and Sodium chloride solution (4g Dissolved in water 1OmL) was added to it. The reaction mass was cooled to 5-10 0 C under nitrogen atmosphere and stirred for 60min. The solid was filtered under vacuum & nitrogen atmosphere and washed the product with 2OmL of chilled water. The solid was dried at 50-60 0 C under nitrogen atmosphere to obtain 18.5g of dry Phenytoin sodium. Yield : approx. 85% w.r.t. Phenytoin
  • Phenytoin (25g) was dissolved in 150 mL of DM water and Sodium hydroxide solution (4.45g dissolved in water 25mL) at 25-30 0 C in a 250 mL four-necked RBF. The reaction mixture was filtered and the clear filtrate was collected and Sodium chloride solution (7.5g Dissolved in water 22mL) was added to it. The reaction mass was cooled to 5-10 0 C under nitrogen atmosphere and stirred for 60min. The solid was filtered under vacuum & nitrogen atmosphere and washed the product with 2OmL of chilled water. The solid was dried at 50-60 0 C under nitrogen atmosphere to obtain 25.3g of dry Phenytoin sodium. Yield : approx. 93% w.r.t. Phenytoin
  • Phenytoin (25g) was dissolved in 150 mL of DM water and Sodium hydroxide solution (4.45g dissolved in water 25mL) at 25-30 0 C in a 250 mL four-necked RBF. The reaction mixture was filtered and the clear filtrate was collected and Sodium chloride solution (1Og Dissolved in water 28mL) was added to it. The reaction mass was cooled to 5-10 0 C under nitrogen atmosphere and stirred for 60min. The solid was filtered under vacuum & nitrogen atmosphere and washed the product with 2OmL of chilled water. The solid was dried at 50-60 0 C under nitrogen atmosphere to obtain 25.9g of dry Phenytoin sodium. Yield: approx. 95.3% w.r.t. Phenytoin
  • Phenytoin (178g) was dissolved in 600 mL of DM water and Sodium hydroxide solution (16.7g dissolved in water 105mL) at 30-40 0 C in a 2 L RBF. The reaction mixture was filtered and the clear filtrate was collected and Sodium chloride solution (2 Ig dissolved in water 32mL) was added to it. The filtrate was cooled to 5-10 0 C under nitrogen atmosphere and stirred for 60min. The solid was filtered under vacuum & nitrogen atmosphere and washed with 10OmL of chilled water. The solid was dried at 50-60 0 C under nitrogen atmosphere to obtain 102.6g of dry Phenytoin sodium.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)

Abstract

The present invention relates to an improved process for the preparation of Phenytoin Sodium of formula (I) by reacting Phenytoin with aqueous solution of Sodium hydroxide in presence of aqueous Sodium chloride.

Description

'AN IMPROVED PROCESS FOR THE PREPARATION OF PHENYTOIN
SODIUM'
Field of the Invention
The present invention relates to an improved process for the preparation of Phenytoin Sodium, a sodium channel blocker used for the treatment of epilepsy.
Background of the Invention
Phenytoin Sodium, which is chemically known as 5,5-Diphenylhydantoin sodium salt is a sodium channel blocker, and has the following structural formula:
Figure imgf000002_0001
(I)
Phenytoin Sodium is a well-known pharmaceutical agent having anticonvulsant and antiepileptic activity and useful in the treatment of epilepsy and it is available in the market under the various brand names such as Aleviatin ®, Persantin ®, Aurantin ®, Dilantin ®, Dintoina ®, Epanutin ® etc.
US Pat. No. 2,409,754 describes a process for preparation of Phenytoin, which is generically known as 5,5-diphenyl-2,4-imidazolidinedione and also known as diphenylhydantoin. According to this patent 5,5-diarylhydantoins is prepared by reacting 1 mole of benzophenone with 1 mole of alkali-metal cyanide and 3 moles of ammonium carbonate in aqueous ethyl alcohol at about 60° C. US Pat. No. 2,684,371 claimed a process for the preparation of highly pure diphenylhydantoin by reacting urea with benzil in an alkaline aqueous methanol reaction medium.
US Pat. No. 3,646,056 describes a process for the preparation of 5,5-diarylhydantoins in one step by reacting benzoin with 1-3 equivalents of urea in an alkaline medium in the presence of 0.5-4 equivalents of elemental sulfur at a temperature between 60° C and the boiling point of the reaction mixture.
US Pat. No. 6,245,917 teaches a process for the preparation of crystalline sodium phenytoin monohydrate by mixing sodium Phenytoin anhydrate and water in an organic solvent selected from toluene, methanol and dichloromethane, at about 300C to about 400C.
In all the above mentioned prior art the yield of Phenytoin sodium is very low. We focused our research to develop an improved and efficient process for the preparation of the compound of formula (I) which will improve the yield by 20 to 30% having high purity.
Objectives of the Invention
The main objective of the present invention is to provide an improved process for the preparation of compound of formula (I) in high yield and high purity.
Another objective of the present invention is to provide a process for the preparation of compound of formula (I), which uses water as a solvent and avoids organic solvents.
Another objective of the present invention is to provide a process for the preparation of compound of formula (I), which is economical and commercially viable.
Summary of the Invention
Accordingly, the present invention provides a process for the preparation of Phenytoin Sodium (I), by reacting of Phenytoin of formula (II) with aqueous solution of sodium hydroxide in presence of aqueous Sodium chloride using water as a solvent at a temperature of about 25° C to 50° C to obtain Phenytoin Sodium of formula (I).
The process is shown in the scheme given below:
Figure imgf000004_0001
(ID (D
Description of the Invention
In an embodiment of the present invention, the aqueous sodium chloride is used in different concentration with respect to Phenytoin where the concentration varies from 10 to 50% preferably 20 to 40%.
In another embodiment of the present invention, the reaction is performed at a temperature of about 5° C to 50° C. Most preferably; the reaction step is performed at a temperature of about 5° C to 30° C.
In yet another embodiment of the present invention the starting material of this invention is prepared according to the literature available in the prior art.
In the present invention none of the organic solvent is used. Moreover, the use of sodium chloride enhances the yield of the product. We carried out the same process without using sodium chloride the yield achieved was approximately 66% whereas by using sodium chloride the yield improved by 20 to 30%. This makes the invention economical and commercially viable.
The invention is further illustrated by the following examples, which should not be construed to limit the scope of the invention in anyway. Example 1
Preparation of Phenytoin Sodium in Water
Phenytoin (2Og) was dissolved in 120 mL of DM water and Sodium hydroxide solution (3.56g dissolved in water 22.5mL) at 25-300C in a 250 mL four-necked RBF. The reaction mixture was filtered and the clear filtrate was collected. The reaction mass was cooled to 5-100C under nitrogen atmosphere and stirred for 60min. The solid was filtered under vacuum & nitrogen atmosphere and washed the product with 2OmL of chilled water. The solid was dried at 50-600C under nitrogen atmosphere to obtain 14.4g of dry Phenytoin sodium. Yield: approx. 66.2% w.r.t. Phenytoin
Example 2
Preparation of Phenytoin Sodium in Water with Sodium chloride (20% w.r.t Phenvtoin)
Phenytoin (2Og) was dissolved in 120 mL of DM water and Sodium hydroxide solution (3.56g dissolved in water 22.5mL) at 25-300C in a 250 mL four-necked RBF. The reaction mixture was filtered and the clear filtrate was collected and Sodium chloride solution (4g Dissolved in water 1OmL) was added to it. The reaction mass was cooled to 5-100C under nitrogen atmosphere and stirred for 60min. The solid was filtered under vacuum & nitrogen atmosphere and washed the product with 2OmL of chilled water. The solid was dried at 50-600C under nitrogen atmosphere to obtain 18.5g of dry Phenytoin sodium. Yield : approx. 85% w.r.t. Phenytoin
Example 3
Preparation of Phenvtoin Sodium in Water with Sodium Chloride (30% w.r.t Phenvtoin)
Phenytoin (25g) was dissolved in 150 mL of DM water and Sodium hydroxide solution (4.45g dissolved in water 25mL) at 25-300C in a 250 mL four-necked RBF. The reaction mixture was filtered and the clear filtrate was collected and Sodium chloride solution (7.5g Dissolved in water 22mL) was added to it. The reaction mass was cooled to 5-100C under nitrogen atmosphere and stirred for 60min. The solid was filtered under vacuum & nitrogen atmosphere and washed the product with 2OmL of chilled water. The solid was dried at 50-600C under nitrogen atmosphere to obtain 25.3g of dry Phenytoin sodium. Yield : approx. 93% w.r.t. Phenytoin
Example 4
Preparation of Phenytoin Sodium in Water with Sodium Chloride (40% w.r.t Phenvtoin)
Phenytoin (25g) was dissolved in 150 mL of DM water and Sodium hydroxide solution (4.45g dissolved in water 25mL) at 25-300C in a 250 mL four-necked RBF. The reaction mixture was filtered and the clear filtrate was collected and Sodium chloride solution (1Og Dissolved in water 28mL) was added to it. The reaction mass was cooled to 5-100C under nitrogen atmosphere and stirred for 60min. The solid was filtered under vacuum & nitrogen atmosphere and washed the product with 2OmL of chilled water. The solid was dried at 50-600C under nitrogen atmosphere to obtain 25.9g of dry Phenytoin sodium. Yield: approx. 95.3% w.r.t. Phenytoin
Example 5
In-situ preparation of Phenytoin Sodium in Water with Sodium chloride (20% w.r.t phenvtoin)
Potassium hydroxide (152g) was dissolved in 96mL of DM water in a 3 L RBF. Methanol (48OmL) was charged at 25-300C and cooled to 0-50C. Urea (49.5g) and lOOg of Benzil was charged at 0-50C. The reaction mixture was refluxed for 60min and 144OmL of water was added to it and was cooled to 00C. 1Og of hyflo & 1Og of activated carbon was added and stirred for 30-60min at 0-5° C. The reaction mixture was filtered through hyflo bed and washed with chilled 10OmL of water and collected into a 3 L RBF. The pH was adjusted to 6.0 - 7.0 with cone, hydrochloric acid at 30-45° C. The slurry was stirred for 30min, filtered and washed with 100OmL hot water to obtain 178. Ig wet Phenytoin having moisture contents 38.7%w/w. The anhydrous weight was found to be 109.2g.
Phenytoin (178g) was dissolved in 600 mL of DM water and Sodium hydroxide solution (16.7g dissolved in water 105mL) at 30-400C in a 2 L RBF. The reaction mixture was filtered and the clear filtrate was collected and Sodium chloride solution (2 Ig dissolved in water 32mL) was added to it. The filtrate was cooled to 5-100C under nitrogen atmosphere and stirred for 60min. The solid was filtered under vacuum & nitrogen atmosphere and washed with 10OmL of chilled water. The solid was dried at 50-600C under nitrogen atmosphere to obtain 102.6g of dry Phenytoin sodium.

Claims

WE CLAIM:
l A process for the preparation of Phenytoin Sodium (I), by reacting Phenytoin of formula (II) with aqueous solution of sodium hydroxide in presence of aqueous Sodium chloride using water as a solvent.
Figure imgf000008_0001
(H)
(D
2. A process according to claim 1, where the sodium chloride is used in the range of 20-40% (w/w) w.r.t. Phenytoin.
3. A process according to claim 1, where the reaction is carried out at a temperature in the range of 25° C to 50° C.
4. A process according to claim 1, where the reaction is carried out at a temperature in the range of 25° C to 30° C.
5. A process according to claim 1, where the obtained Phenytoin sodium is isolated at a temperature in the range of 5-100C.
PCT/IB2007/001130 2006-05-04 2007-05-02 An improved process for the preparation of phenytoin sodium Ceased WO2007129184A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN806/CHE/2006 2006-05-04
IN806CH2006 2006-05-04

Publications (2)

Publication Number Publication Date
WO2007129184A2 true WO2007129184A2 (en) 2007-11-15
WO2007129184A3 WO2007129184A3 (en) 2009-06-04

Family

ID=38668137

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2007/001130 Ceased WO2007129184A2 (en) 2006-05-04 2007-05-02 An improved process for the preparation of phenytoin sodium

Country Status (1)

Country Link
WO (1) WO2007129184A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109456271A (en) * 2018-11-20 2019-03-12 宁波职业技术学院 A kind of synthetic method of dilantin sodium
CN111978258A (en) * 2020-08-13 2020-11-24 山西新宝源制药有限公司 Method for preparing phenytoin sodium

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6245917B1 (en) * 1998-03-20 2001-06-12 Warner-Lambert Company Crystalline sodium phenytoin monohydrate

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109456271A (en) * 2018-11-20 2019-03-12 宁波职业技术学院 A kind of synthetic method of dilantin sodium
CN109456271B (en) * 2018-11-20 2022-06-21 宁波职业技术学院 Synthesis method of phenytoin sodium
CN111978258A (en) * 2020-08-13 2020-11-24 山西新宝源制药有限公司 Method for preparing phenytoin sodium

Also Published As

Publication number Publication date
WO2007129184A3 (en) 2009-06-04

Similar Documents

Publication Publication Date Title
CA2726599C (en) Process for treprostinil salt preparation
CA2707334C (en) A process for the preparation or purification of olmesartan medoxomil
CN112088155A (en) Process for the preparation of 2- [ [5- (3-chlorophenyl) -3-hydroxypyridine-2-carbonyl ] amino ] acetic acid
CN108003105B (en) A kind of method for synthesizing small molecule amino acid derivative ectoine
JP2005504800A (en) Method for producing pyrimidinone compounds and pharmaceutically acceptable salts thereof
WO2007129184A2 (en) An improved process for the preparation of phenytoin sodium
US11512044B2 (en) Method for preparing salicylamine acetate
EA004633B1 (en) Process for the synthesis of tetrazol derivatives
EP1311485A1 (en) Processes for preparing cilostazol
CN116162057B (en) Preparation method of 5-sulfonyl-1, 4 dihydropyridine compound
JPH11279129A5 (en)
RU2425038C2 (en) Method of producing 1-[di (4-cyanophenyl)methyl]-1,2,4-triazole
KR100662110B1 (en) Method for preparing tetrazole derivatives
JP4790901B2 (en) Process for producing 4-amino-5-cyanoimidazole derivative and its intermediate
JP2000229936A (en) Production of guanidine derivative
IL134228A (en) Process for preparing heterocyclic compounds
FI57404B (en) FRAMEWORK FOR CYCLING OF NEW N-SUBSTITUTES
JP3790880B2 (en) Novel trilithium salt or tripotassium salt hydrate of 2,4,6-trimercapto-1,3,5-triazine, and method for producing hydrate and anhydride
EP1963309B1 (en) Method for producing metal salts of losartan
CN111196781B (en) Improved method for preparing pentafluoride
JPWO2019157426A5 (en)
EP2022790A1 (en) A process for the preparation or purification of olmesartan medoxomil
WO2007039919A1 (en) Crystalline forms of anastrozole
JP5112737B2 (en) Method for producing aminoimidazole derivative
CA2610665A1 (en) Hydrates of alkaline-earth salts of irbesartan and the preparation thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07734447

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07734447

Country of ref document: EP

Kind code of ref document: A2